Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab added to carboplatin + paclitaxel for epithelial ovarian cancer
ISRCTN91273375Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Oct 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, carboplatin and paclitaxel in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Medical Research Council. Primary endpoint: Progression-free survival. Started Oct 2006; status: completed.
02
Drugs
bevacizumabcarboplatinpaclitaxel
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN91273375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN91273375.